Inhibition of human colorectal cancer metastasis by notoginsenoside R1, an important compound from Panax notoginseng

Lee, Chang-Yin; Hsieh, Shu‐Ling; Hsieh, Shuchen; Tsai, C.-F.; Hsieh, Lan-Chi; Kuo, Yu-Hao; Wu, Chih-Chung

doi:10.3892/or.2016.5222

Cited by 51 publications

(35 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NGR1 is a kind of TCM to potentiate blood circulation and dispel blood stasis, which has been applied for the treatment of cancers, nervous system ailments and cardiovascular system ailments . A substantial amount of research has disclosed that the cardio‐protective activity of NGR1 was principally in the ischemia‐reperfusion injury model .…”

Section: Discussionmentioning

confidence: 99%

“…Notoginsenoside R1 (NGR1) is a sort of traditional Chinese herbal medicine (TCM) extract originating from Panax notoginseng . NGR1 has profuse pharmacological activities, including antitumor, anti‐inflammation, cardioprotection and neuroprotection . NGR1 has been found to take part in modulating cell proliferation, migration and apoptosis in diverse aliments .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Retracted: Notoginsenoside R1 protects WI‐38 cells against lipopolysaccharide‐triggered injury via adjusting the miR‐181a/TLR4 axis

Qian

Shao

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Notoginsenoside R1 (NGR1) is a neoteric phytoestrogen extracted from Panax notoginseng, and possesses comprehensive pharmacological functions in multitudinous ailments. But, whether NGR1 is utilized in neonatal pneumonia is not clear. This research study aspired to disclose the protective activity of NGR1 in neonatal pneumonia. WI-38 cells were co-stimulated with NGR1 and lipopolysaccharide (LPS, 10 ng/mL), CCK-8 and flow cytometry assays were implemented for cell viability and apoptosis assessment. Real-time quantitative plymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and Western blot analysis were executed for inflammatory cytokine determination. MicroRNA-181a (miR-181a) expression was evaluated through RT-qPCR, simultaneously, the impact of miR-181a was estimated in NGR1 and LPS co-managed cells. Dual luciferase report assay was performed to disclose the relation between miR-181a and Toll-like receptor 4 (TLR4). The nuclear factor-κB (NF-κB) and TAK1/JNK pathways were ultimately appraised.We found that NGR1 decreased cell viability, evoked apoptosis and impeded interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) expression and secretions in LPS-managed WI-38 cells. MiR-181a expression was enhanced by NGR1, and miR-181a inhibition inverted the impacts of NGR1 in LPSmanaged WI-38 cells. Besides, TLR4 was predicted to be a firsthand direct target of miR-181a. Furthermore, NGR1 hindered NF-κB and TAK1/JNK pathways through modulating TLR4. These discoveries disclosed the fact that NGR1 protected WI-38 cells against LPS-triggered injury via adjusting the miR-181a/ TLR4 and NF-κB and TAK1/JNK pathways. K E Y W O R D SmicroRNA-181a, neonatal pneumonia, NF-κB, notoginsenoside R1, TAK1/JNK, toll-like receptor 4 | INTRODUCTIONNeonatal pneumonia is a universal ailment among newborns, and is also a major reason for neonatal death. 1 Statistical evidence displays that about 156 million new events of neonatal pneumonia take place around the world each year, and 95% of neonatal pneumonia episodes happen in the developing countries. 2 The clinical manifestations of neonatal pneumonia comprise fever, cough, dyspnea, heart failure, sepsis, and even death. 3,4 The causes of neonatal pneumonia are multitudinous and are linked to malnutrition, unsafe sanitation,

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Retracted: Notoginsenoside R1 protects WI‐38 cells against lipopolysaccharide‐triggered injury via adjusting the miR‐181a/TLR4 axis

Qian

Shao

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Such protease regulation was also observed in breast cancer cells treated with astragaloside IV [47]. Notoginsenoside R1 (NGR1) is a primary compound in Panax notoginseng, and its antimetastatic property has also been revealed [48]. NGR1 can inhibit the migration, invasion, and adhesion of cultured human colorectal cancer cells (HCT-116) via suppressing MMP-9, integrin-1, E-selectin, and ICAM-1 expressions.…”

Section: Suppression Of Proteases Expressionmentioning

confidence: 88%

Recent Progress on the Molecular Mechanisms of Anti-invasive and Metastatic Chinese Medicines for Cancer Therapy

Wei¹,

Wang²,

Feng³

2017

Unique Aspects of Anti-Cancer Drug Development

View full text Add to dashboard Cite

Despite of the recent advances in diagnostic and therapeutic approaches, cancer remains as the leading cause of death worldly with diverse causal factors regarding genes and environment. Invasion and metastasis, as one of the most important hallmarks for cancer, have restrained the successful clinical therapy and are the primary causes of death among cancer patients. So far, most chemotherapeutic drugs are not effective for metastatic cancer due to drug resistance and serious side effects. Therefore, it is urgently essential to develop more effective therapeutic methods. Owing to their diverse biological activities and low toxicity, naturally active compounds derived from Chinese medicines, as a complementary and alternative approach, are reported to promote the therapeutic index and provoked as an excellent source for candidates of anti-metastatic drugs. With the rapid development of molecular biology techniques, the molecular mechanisms of the effects of potential anti-invasive and metastatic Chinese medicines are gradually elucidated. This chapter reviews the potential anti-invasive and metastatic mechanisms of naturally active compounds from Chinese medicines, including suppression of EMT, proteases and cancer-induced angiogenesis, anoikis regulation of circulating tumor cells and regulation of miRNA-mediated gene expression, providing scientific evidence for clinically using Chinese medicines in the field of cancer therapy.

show abstract

“…Panax notoginseng has beneficial effects on atherosclerotic diseases such as cardiovascular disease (Yang et al , ), cerebral ischemic disease (Shi et al , ) and other diseases including diabetes (Uzayisenga et al , ; Kitamura et al , ), tumor (Yang et al , ; Li et al , ; Lee et al , ), hepatic injury (Wang et al , ; Zhang et al , ) and bone fracture (Wang et al, ). For in the cardiovascular system, it attenuates atherosclerosis, through inhibiting the formation of foam cells and lowering cholesterol ester level (Jia et al , ), demonstrating antiinflammatory and anti‐adhesion effects (Yuan et al , ) and reducing the size of atherosclerotic plaques (Liu et al , ).…”

Section: Discussionmentioning

confidence: 99%

Panax notoginsengPreparations for Unstable Angina Pectoris: A Systematic Review and Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

This paper assessed the evidence of Panax notoginseng preparations in patients suffering from UAP using meta-analysis and systematic review methods. Methods were according to the Cochrane Handbook and analysed using Revman 5.3. A search of PubMed, Cochrane Library, Embase, MEDLINE, Chinese national knowledge infrastructure (CNKI), Vip information database, Wanfang data and Chinese Biomedical Literature Database (SinoMed) was conducted to identify randomized controlled trials (RCTs) of P. notoginseng preparations on UAP regardless of blinding, sex and language. The outcomes include all-cause mortality, cardiac mortality, cardiovascular events, UAP symptoms, improvement of electrocardiogram and adverse events. Eighteen RCTs including 1828 patients were identified. The level of reporting is generally poor. Among 18 studies, 16 studies were prescribed P. notoginseng injections, and two studies were oral P. notoginseng preparations. Reduction of cardiovascular events (RR:0.35;95% CI:0.13 to 0.94), alleviation of angina pectoris symptoms (RR:1.23;95% CI 1.18 to 1.29), improvement of ECG (RR:1.22;95% CI 1.15 to 1.28) and reduced frequency of angina pectoris (MD:-1.48; 95% CI -2.49 to -0.48) were observed. Cardiac mortality and duration of angina pectoris were not statistically significant. Panax notoginseng is beneficial to UAP patients; the results of these reviews may have important implications to clinical work. Copyright © 2017 John Wiley & Sons, Ltd.

show abstract

Inhibition of human colorectal cancer metastasis by notoginsenoside R1, an important compound from Panax notoginseng

Cited by 51 publications

References 49 publications

Retracted: Notoginsenoside R1 protects WI‐38 cells against lipopolysaccharide‐triggered injury via adjusting the miR‐181a/TLR4 axis

Retracted: Notoginsenoside R1 protects WI‐38 cells against lipopolysaccharide‐triggered injury via adjusting the miR‐181a/TLR4 axis

Recent Progress on the Molecular Mechanisms of Anti-invasive and Metastatic Chinese Medicines for Cancer Therapy

Panax notoginsengPreparations for Unstable Angina Pectoris: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About